Expert Opinion on Investigational Drugs

Papers
(The TQCC of Expert Opinion on Investigational Drugs is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (70 mg/mL100
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy77
SGLT2 inhibitors: an evidence-based update on cardiovascular implications63
Theranostic strategies in sarcoma: preliminary clinical evidence51
A randomized, Phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men46
Investigational agents targeting alarmins for asthma treatment: insights and progress from phase I and II trials40
Current status and perspective of immunotherapy for head and neck squamous cell carcinoma39
Endoglin-targeted cancer therapies: current status and opportunities39
Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?36
Safety, pharmacokinetics, and efficacy of HY-072808 ointment, a novel PDE4 inhibitor, in adolescent and adult patients with mild-to-moderate AD36
New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology32
Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?29
The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy26
Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies26
Management of inflammaging in kidney diseases: focusing on the current investigational drugs25
Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome25
An overview of KRAS-targeting therapies for colorectal cancer in phase I and II development25
Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis24
Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval24
CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors23
Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development23
Novel precision therapies for cholangiocarcinoma: an overview of clinical trials23
The role of 5-HT modulation in opioid withdrawal and neonatal opioid withdrawal syndrome: mechanisms and potential serotonergic targets22
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese su22
Mass balance and absolute bioavailability of avenciguat ( 14 C) after intravenous or oral administration in healthy male participants21
Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies21
Endothelin receptor antagonists for diabetic kidney disease: back to the future?21
Investigational drugs for the treatment of dysmenorrhea20
Potassium channel modulators and schizophrenia: an overview of investigational drugs19
IgA nephropathy: an overview of drug treatments in clinical trials19
Investigational new drug approval of DA-1241: what we know about GPR119 targeting for MASH therapy?19
Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease19
Recent developments in adjunct therapies for type 1 diabetes18
Investigational drugs for immune thrombocytopenia18
Assessing the clinical potential of plozasiran, an APOC3 siRNA therapy for severe hypertriglyceridemia18
Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials18
Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development17
Duchenne muscular dystrophy: promising early-stage clinical trials to watch17
What is the progress of experimental drug development for fibromyalgia?16
Investigational new drugs for the treatment of leishmaniasis16
NF1 alterations in cancers: therapeutic implications in precision medicine16
Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal16
Clinical application and potential pluripotent effects of hepatocyte growth factor in spinal cord injury regeneration16
Preclinical therapeutics for sickle cell disease: modern developments and future considerations15
Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study14
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists14
Current experimental and early investigational agents for cardiac fibrosis: where are we at?14
Treatment of anemia in myelofibrosis: focusing on novel therapeutic options14
Investigational regenerative medicine for non-traumatic osteonecrosis of the femoral head: a survey of registered clinical trials14
Targeting a key FAK-tor: the therapeutic potential of combining focal adhesion kinase (FAK) inhibitors and chemotherapy for chemoresistant non-small cell lung cancer14
Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC)13
Progress in the treatment of anal cancer: an overview of the latest investigational drugs13
Investigational drugs for glaucoma: novel mechanistic approaches of preclinical agents13
Investigative agents for atrial fibrillation: agonists and stimulants, progress and expectations13
Assessing the clinical progress of the bispecific nanobody sonelokimab13
MASLD and MASH: how a change of nomenclature may impact our approach in treating liver disease13
Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 partici13
Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects13
Glucagon‑like peptide‑1 receptor agonists in multiple sclerosis: therapeutic promise, challenges, and future directions13
Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions13
JAK inhibitors for rheumatoid arthritis13
Frontotemporal dementia: from genetics to therapeutic approaches13
Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 202113
KAT6 inhibitors under investigation for solid tumors: the preclinical and early phase progress12
Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management?12
Investigational agents for pancreatic neuroendocrine tumors: what clinical progress have we seen in the last 5 years?12
Navafenterol for chronic obstructive pulmonary disease therapy12
Clinical development of tri-specific antibodies for immune-oncology12
Investigational drugs for the treatment of olfactory dysfunction12
Is seltorexant, an orexin-2 receptor antagonist, showing promise in insomnia?12
First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor Xa and factor IIa12
Investigational thrombolytic drugs for acute ischemic stroke12
An update on novel investigational agents for the treatment of primary biliary cholangitis11
Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia11
Pharmacological agents for bone fracture healing: talking points from recent clinical trials11
Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis11
Immunotherapeutic strategies for treating opioid use disorder and overdose11
Antibiotics and non-traditional antimicrobial agents for Pseudomonas aeruginosa in clinical phases 1, 2, and 3 trials11
Zelenectide pevedotin (BT-8009): a bicyclic peptide toxin conjugate targeting nectin-4 for the treatment of bladder cancer11
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus11
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents11
Investigational agents for ischaemic cardiomyopathy treatment: preclinical and early phase insights11
Investigational new drugs for the treatment of Dravet syndrome: an update11
Inflammation and Huntington’s disease – a neglected therapeutic target?10
Assessing potential of psilocybin for depressive disorders10
A four-in-one first-in-human study to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and concentration-QTc relationship of HRS-1780, a selective non-steroidal mineralocorticoid recep10
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers10
Potential of BGB-11417, a BCL2 inhibitor, in hematological malignancies10
Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study10
The latest investigational drugs for patients with allergic rhinitis9
Menin inhibitors for adult acute myeloid leukemia: 2025 update9
Approaches to combating methicillin-resistant Staphylococcus aureus (MRSA) biofilm infections9
Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress9
Tafoxiparin effects on cervical ripening and labor augmentation9
The impact of current investigational drugs for acne on future treatment strategies9
The bispecific antibody AZD0486: an overview of the clinical journey to date with a focus on follicular lymphoma9
Investigational insights into the potential of angiotensin type II receptor agonists as therapeutics for idiopathic pulmonary fibrosis9
Prospects of current AXL-targeting therapies in early phase cancer trials9
Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials9
0.44926190376282